The Academy of Managed Care Pharmacy (AMCP) supports scientifically sound research that compares the effectiveness and value of prescription drugs, as well as research aimed at tailoring treatment options to individual patients’ needs.
Government & Advocacy
AMCP advocates on behalf of managed care pharmacy professionals to ensure that their interests and the patients they serve are considered in federal and state health care policy decisions.
Featured Legislative & Regulatory Positions
See all Positions
AMCP supports the recognition of pharmacists as providers. When pharmacists are recognized as provider members of the health care team, patient outcomes improve, and patients report higher rates of satisfaction while overall health care costs are reduced. Recognized provider status would allow pharmacists to be reimbursed for providing health care services to patients. In a survey conducted in 2023 commissioned by Wolters Kluwer Health, 58% of Americans agreed that they are more likely to seek non-emergency medical care from a pharmacist.
AMCP supports increased access to Prescription Digital Therapeutics (PDTs). PDTs are software-based therapies that deliver clinical benefits to patients, either alone or in combination with other forms of treatment. These therapeutics require a prescription and are subject to oversight by the Food and Drug Administration (FDA). To be approved by the FDA, PDTs must demonstrate both safety and efficacy.
Featured Resources
See More Resources
Regulatory Updates
Letters, Statements, and Analysis
See All Letters, Statements, & Analysis
The Protecting Pharmacies in Medicaid Act would prohibit the use of spread pricing arrangements in Medicaid programs. Pharmacy benefit managers (PBMs) would be required to pass through to pharmacies the full amount of the money paid to the PBMs by Medicaid programs, except for a fixed administrative fee. The total reimbursement amount will be determined by a survey of national average drug acquisition costs administered by the Department of Health & Human Services.
In AMCP's latest comments to the FDA, we emphasize the need for standardized public reporting of confirmatory trial progress, ensuring payers and health care providers have the necessary data to make informed coverage decisions. By supporting proactive communication and rigorous confirmatory trials, AMCP aims to balance early access to innovative treatments with patient safety and long-term therapeutic value.
Over the weekend, Congressional leadership released a continuing resolution (CR) that extends government funding at the same level as the previous fiscal year, through September 30. Congress must extend government funding by March 14 to avoid a government shutdown.
Latest NewsBREAKS & Briefings
Explore Policy Resource
Take Action
Grassroots Advocacy
AMCP represents managed care pharmacy in meetings with federal lawmakers and regulators and submits comments on proposed rules and regulations. We need and urge your participation in this process through our grassroots advocacy program.
